-
WilmerHale Advises Embark Veterinary in $75M Series B Funding
7.27.2021On July 26, 2021, Embark Veterinary, Inc., the top rated provider of dog DNA tests, announced that it secured $75 million in a Series B funding round led by SoftBank.
-
2021 IPO, Venture Capital and M&A Reports
4.26.2021WilmerHale’s annual IPO, Venture Capital and M&A Reports offer insights into market conditions and provide comprehensive statistics and analysis that are hard to find elsewhere.
-
2021 IPO Report
4.26.2021The 2021 IPO Report offers a detailed IPO market review and outlook, plus useful market metrics and articles on topics of interest for pre-IPO companies.
-
2021 Venture Capital Report
4.26.2021The 2021 Venture Capital Report offers an in-depth US venture capital market review and outlook, including industry and regional breakdowns, as well as insights on a number of key topics.
-
2021 M&A Report
4.26.2021The 2021 M&A Report provides a detailed global M&A market review and outlook, as well as insights on key topics.
-
WilmerHale Advises Volastra Therapeutics in Extended $44M Seed Financing
4.6.2021On April 6, 2021, Volastra Therapeutics, a biotechnology company developing novel therapies for the prevention and treatment of metastatic cancer, announced the extension of its original $12 million seed round to a total of $44 million.
-
Recent Venture Financings as Company Counsel: 2021
3.5.2021In 2020, we served as counsel in more than 200 venture financings raising in excess of $10 billion, including some of the largest and most prominent deals of the year. Since 2010, we have handled approximately 2,700 venture financings with total proceeds in excess of $48 billion.
-
WilmerHale Advises Xilio Therapeutics In $95M Series C Financing
2.25.2021On February 24, 2021, Xilio Therapeutics, a biotechnology company developing potent, tumor-selective immunotherapies for patients with cancer, announced the successful closing of a $95 million Series C financing round.
-
WilmerHale Represents Verve Therapeutics in $94M Series B Financing
1.22.2021On January 19, 2021, Verve Therapeutics, a biotech company pioneering gene editing medicines to treat cardiovascular disease, announced the successful completion of a $94 million Series B financing.
-
WilmerHale Advises Werewolf Therapeutics in $72M Series B Financing
1.8.2021On January 7, 2021, Werewolf Therapeutics, an oncology biotherapeutics company advancing a pipeline of next-generation, transformative cancer treatments, announced the completion of its $72 million Series B financing.
-
2020 IPO, Venture Capital and M&A Reports
6.29.2020WilmerHale’s annual IPO, Venture Capital and M&A Reports offer insights into market conditions and provide comprehensive statistics and analysis that are hard to find elsewhere.
-
2020 M&A Report
6.29.2020The 2020 M&A Report provides a detailed global M&A market review and outlook, as well as insights on key topics.
-
2020 IPO Report
6.29.2020The 2020 IPO Report offers a detailed IPO market review and outlook, plus useful market metrics and articles on topics of interest for pre-IPO companies.
-
2020 Venture Capital Report
6.29.2020The 2020 Venture Capital Report offers an in-depth US venture capital market review and outlook, including industry and regional breakdowns, as well as insights on a number of key topics.
-
COVID-19: Understanding the Paycheck Protection Loan Program and Expansion of the Emergency Economic Injury Disaster Loan Programs Under the CARES Act
3.30.2020On Friday, March 27, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) became law.
